Re-Examining the Role of Radiation Therapy for Diffuse Large B-Cell Lymphoma in the Modern Era-Reference-Cited by-同舟云学术

Re-Examining the Role of Radiation Therapy for Diffuse Large B-Cell Lymphoma in the Modern Era

Published:2016-05-01 Issue:13 Volume:34 Page:1443-1447
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Ng Andrea K.¹,Dabaja Bouthaina Shbib²,Hoppe Richard T.³,Illidge Timothy⁴,Yahalom Joachim⁵

Affiliation:

1. Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

2. The University of Texas MD Anderson Cancer Center, Houston, TX

3. Stanford University School of Medicine, Stanford, CA

4. University of Manchester, Manchester Academic Health Sciences Centre, The Christie National Health Service Foundation Trust, Manchester, United Kingdom

5. Memorial Sloan Kettering Cancer Center, New York, NY

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2015.64.9418

Reference35 articles.

1. Treatment Selection and Survival Outcomes in Early-Stage Diffuse Large B-Cell Lymphoma: Do We Still Need Consolidative Radiotherapy?

2. What is the optimal management of early-stage low-grade follicular lymphoma in the modern era?

3. Management Trends and Outcomes for Stage I to II Mantle Cell Lymphoma Using the National Cancer Data Base: Ascertaining the Ideal Treatment Paradigm

4. Treatment Selection and Outcomes in Early-Stage Classical Hodgkin Lymphoma: Analysis of the National Cancer Data Base

5. Early-Stage Classic Hodgkin Lymphoma: The Utilization of Radiation Therapy and Its Impact on Overall Survival

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era;BMC Cancer;2024-01-13

2. Hypofractionated Radiotherapy for Refractory or Relapsed Aggressive B-cell Lymphoma in the Rituximab Era;2023-08-30

3. Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005–2018);Cancer Pathogenesis and Therapy;2023-01

4. PET-guided treatment for personalised therapy of Hodgkin lymphoma and aggressive non-Hodgkin lymphoma;The British Journal of Radiology;2021-11-01

5. Efficacy of Palliative Radiation Therapy (RT) for Chemotherapy Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Population-Based Retrospective Review;Practical Radiation Oncology;2021-03